WANBURY

Wanbury Limited

API and branded formulations pharmaceutical manufacturer

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹192.36
Market cap
671 Cr
Stock P/E
12.0
P/B
4.65
Dividend yield
0.5%
ROE (FY25)
51.5%
ROCE (FY25)
28.6%
Operating margin (FY25)
10.5%
Debt / equity (FY25)
2.92
OCF / EBITDA (FY26)
29.5%
OCF / EBITDA (3Y)
24.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Wanbury makes active pharmaceutical ingredients (APIs), the bulk drug materials used in medicines, mainly for regulated markets such as the European Union, Brazil and the US, and also sells branded formulations in India.

Company snapshot

98thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Return on equity of 51.5% — the company generates strong returns on shareholders' money.
Concerns
  • ✗Only 24% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales144 Cr145 Cr139 Cr131 Cr161 Cr133 Cr172 Cr163 Cr160 Cr162 Cr165 Cr166 Cr
Operating expenses (approx.)127 Cr124 Cr121 Cr120 Cr141 Cr120 Cr142 Cr139 Cr134 Cr136 Cr135 Cr149 Cr
EBITDA17 Cr21 Cr18 Cr11 Cr20 Cr14 Cr30 Cr24 Cr26 Cr27 Cr30 Cr16 Cr
OPM %12.0%14.5%13.0%8.4%12.4%10.4%17.2%15.0%16.1%16.4%18.1%9.8%
Other income0.76 Cr0.69 Cr0.93 Cr0.94 Cr2 Cr0.84 Cr2 Cr0.35 Cr0.20 Cr0.18 Cr0.21 Cr0.36 Cr
Interest8 Cr8 Cr7 Cr8 Cr10 Cr10 Cr9 Cr8 Cr7 Cr7 Cr8 Cr8 Cr
Depreciation3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr4 Cr4 Cr4 Cr3 Cr4 Cr
Profit before tax7 Cr10 Cr8 Cr1 Cr8 Cr1 Cr19 Cr14 Cr15 Cr16 Cr15 Cr5 Cr
Tax %-2.5%-0.2%3.3%0.0%1.8%5.8%-6.3%0.8%-0.1%0.7%-43.1%29.3%
Net profit7 Cr10 Cr8 Cr1 Cr8 Cr1 Cr20 Cr13 Cr15 Cr16 Cr22 Cr3 Cr
EPS (₹)₹2.25₹3.14₹2.47₹0.32₹2.44₹0.76₹6.18₹4.12₹4.58₹4.52₹7.33₹0.93

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales437 Cr374 Cr391 Cr367 Cr393 Cr511 Cr500 Cr576 Cr600 Cr650 CrSign in free for the trailing twelve months
Operating expenses (approx.)418 Cr442 Cr376 Cr344 Cr374 Cr476 Cr476 Cr506 Cr523 Cr544 CrSign in free for the trailing twelve months
EBITDA19 Cr-67 Cr16 Cr23 Cr18 Cr35 Cr23 Cr70 Cr76 Cr107 CrSign in free for the trailing twelve months
OPM %4.3%-18.0%4.0%6.4%4.6%6.9%4.6%12.2%12.7%16.4%Sign in free for the trailing twelve months
Other income8 Cr76 Cr9 Cr1 Cr2 Cr2 Cr0.91 Cr3 Cr3 Cr0.94 CrSign in free for the trailing twelve months
Interest21 Cr31 Cr40 Cr33 Cr23 Cr21 Cr21 Cr29 Cr37 Cr30 CrSign in free for the trailing twelve months
Depreciation10 Cr10 Cr10 Cr10 Cr10 Cr11 Cr12 Cr13 Cr13 Cr14 CrSign in free for the trailing twelve months
Profit before tax-5 Cr-32 Cr-25 Cr65 Cr-12 Cr81 Cr-10 Cr31 Cr30 Cr60 CrSign in free for the trailing twelve months
Tax %-9.7%1.2%0.5%0.3%-1.6%-0.4%-1.1%1.2%-3.3%-10.6%Sign in free for the trailing twelve months
Net profit-5 Cr-32 Cr-25 Cr64 Cr-13 Cr81 Cr-10 Cr30 Cr31 Cr66 CrSign in free for the trailing twelve months
EPS (₹)₹-2.47₹-13.49₹-10.48₹26.90₹-5.04₹26.88₹-6.18₹9.29₹9.32₹20.55Sign in free for the trailing twelve months
Dividend payout %—————0.0%—10.3%0.0%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital23 Cr24 Cr24 Cr25 Cr25 Cr33 Cr33 Cr33 Cr33 Cr35 Cr
Reserves-191 Cr-183 Cr-207 Cr-143 Cr-156 Cr-30 Cr-40 Cr-5 Cr27 Cr110 Cr
Borrowings324 Cr182 Cr208 Cr124 Cr88 Cr67 Cr64 Cr110 Cr173 Cr215 Cr
Other liabilities261 Cr248 Cr260 Cr271 Cr330 Cr282 Cr245 Cr206 Cr181 Cr158 Cr
Total liabilities417 Cr270 Cr285 Cr277 Cr288 Cr351 Cr302 Cr343 Cr414 Cr518 Cr
Fixed assets (net)185 Cr178 Cr172 Cr159 Cr158 Cr149 Cr152 Cr149 Cr190 Cr227 Cr
CWIP10 Cr10 Cr9 Cr14 Cr11 Cr2 Cr2 Cr3 Cr5 Cr25 Cr
Investments0.0091 Cr0.02 Cr0.02 Cr0.0068 Cr0.01 Cr0.0093 Cr0.01 Cr0.03 Cr0.15 Cr0.03 Cr
Inventories34 Cr13 Cr19 Cr12 Cr25 Cr50 Cr22 Cr36 Cr38 Cr51 Cr
Trade receivables91 Cr29 Cr44 Cr51 Cr34 Cr63 Cr68 Cr89 Cr114 Cr143 Cr
Cash & bank10 Cr3 Cr3 Cr3 Cr10 Cr22 Cr1 Cr3 Cr4 Cr2 Cr
Other assets87 Cr37 Cr37 Cr38 Cr49 Cr65 Cr58 Cr63 Cr63 Cr70 Cr
Total assets417 Cr270 Cr285 Cr277 Cr288 Cr351 Cr302 Cr343 Cr414 Cr518 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity43 Cr—30 Cr44 Cr17 Cr38 Cr20 Cr4 Cr26 Cr32 Cr
Cash from investing-14 Cr—-3 Cr64 Cr8 Cr0.59 Cr-9 Cr-17 Cr-51 Cr-56 Cr
Cash from financing-26 Cr—-27 Cr-108 Cr-17 Cr-26 Cr-32 Cr15 Cr26 Cr22 Cr
Net cash flow3 Cr—-0.13 Cr-0.09 Cr7 Cr13 Cr-21 Cr2 Cr0.66 Cr-2 Cr
Free cash flow (OCF − Capex)29 Cr—25 Cr36 Cr17 Cr38 Cr20 Cr4 Cr-23 Cr-28 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
ROCE %—-343.2%———54.7%34.4%62.0%28.6%
ROE %———————200.3%51.5%
Debtor days762943503245505769
Inventory days823755314259314549
Days payable310232318304228229210205181
Cash conversion cycle-152-166-220-223-154-125-129-103-63
OCF / EBITDA %230.0%——188.2%92.6%106.4%85.4%5.7%34.2%
OCF / EBITDA % (3 years)—————128.1%96.8%47.7%29.4%
Debt / equity—0.00—————3.942.92
Current ratio0.610.220.260.290.270.480.380.741.11
Net debt / EBITDA16.67——5.204.351.262.701.522.22